Nadofaragene firadenovec - FKD Therapies
Alternative Names: AAV-IFN-apha-2b-gene-therapy-FKD-Therapies; Adenovirus-Delivered Interferon Alpha-2b; Adstiladrin; FE-999326; Instiladrin; Nadofaragene firadenovec-vncg; Nadofaragene firadenovec/Syn3; rAd-IFNα; rAd-IFNα/Syn3; SCH-209702/SCH-721015; SCH-721015; SCH-721015/SCH-209702; TR-002Latest Information Update: 23 Aug 2024
At a glance
- Originator Schering-Plough
- Developer Ferring Pharmaceuticals; FKD Therapies; Trizell; University of Pennsylvania
- Class Antineoplastics; IFNA2B gene therapies; Immunotherapies
- Mechanism of Action Gene transference; IFNA2B expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bladder cancer
- Phase III Malignant-mesothelioma
Most Recent Events
- 08 Aug 2024 Ferring Pharmaceuticals plans phase II ABLE-22 trial in Bladder cancer (Monotherapy, Combination therapy, Locally recurrent) in August 2024 (Intravesical, Infusion) (NCT06545955)
- 29 Jul 2024 Ferring Pharmaceuticals plans a phase IIIb ABLE-32 trial for Bladder cancer in August 2024 (IV) (NCT06510374)
- 06 May 2024 Efficacy and adverse events data from phase III trial in Bladder cancer released by Ferring Pharmaceuticals